Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 291

1.

Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis.

Zhang J, Li Y, Liu Q, Lu W, Bu G.

Oncogene. 2010 Jan 28;29(4):539-49. doi: 10.1038/onc.2009.339. Epub 2009 Nov 2.

2.

SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer.

Wang H, He L, Ma F, Regan MM, Balk SP, Richardson AL, Yuan X.

J Biol Chem. 2013 Mar 1;288(9):6478-87. doi: 10.1074/jbc.M112.419184. Epub 2013 Jan 10.

3.

Cooperative signaling between Wnt1 and integrin-linked kinase induces accelerated breast tumor development.

Oloumi A, Maidan M, Lock FE, Tearle H, McKinney S, Muller WJ, Aparicio SA, Dedhar S.

Breast Cancer Res. 2010;12(3):R38. doi: 10.1186/bcr2592. Epub 2010 Jun 21.

4.

Protein kinase CK2 in mammary gland tumorigenesis.

Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD, Seldin DC.

Oncogene. 2001 May 31;20(25):3247-57.

5.

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies.

Ettenberg SA, Charlat O, Daley MP, Liu S, Vincent KJ, Stuart DD, Schuller AG, Yuan J, Ospina B, Green J, Yu Q, Walsh R, Li S, Schmitz R, Heine H, Bilic S, Ostrom L, Mosher R, Hartlepp KF, Zhu Z, Fawell S, Yao YM, Stover D, Finan PM, Porter JA, Sellers WR, Klagge IM, Cong F.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15473-8. doi: 10.1073/pnas.1007428107. Epub 2010 Aug 16.

6.

LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.

Liu CC, Prior J, Piwnica-Worms D, Bu G.

Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5136-41. doi: 10.1073/pnas.0911220107. Epub 2010 Mar 1.

7.

Both LRP5 and LRP6 receptors are required to respond to physiological Wnt ligands in mammary epithelial cells and fibroblasts.

Goel S, Chin EN, Fakhraldeen SA, Berry SM, Beebe DJ, Alexander CM.

J Biol Chem. 2012 May 11;287(20):16454-66. doi: 10.1074/jbc.M112.362137. Epub 2012 Mar 20.

8.

The Wnt co-receptor Lrp6 is required for normal mouse mammary gland development.

Lindvall C, Zylstra CR, Evans N, West RA, Dykema K, Furge KA, Williams BO.

PLoS One. 2009 Jun 5;4(6):e5813. doi: 10.1371/journal.pone.0005813.

9.

Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice.

Huang S, Li Y, Chen Y, Podsypanina K, Chamorro M, Olshen AB, Desai KV, Tann A, Petersen D, Green JE, Varmus HE.

Genome Biol. 2005;6(10):R84. Epub 2005 Sep 30.

10.

Wnt5a suppresses tumor formation and redirects tumor phenotype in MMTV-Wnt1 tumors.

Easter SL, Mitchell EH, Baxley SE, Desmond R, Frost AR, Serra R.

PLoS One. 2014 Nov 17;9(11):e113247. doi: 10.1371/journal.pone.0113247. eCollection 2014.

11.

Overexpression of the tumor suppressor gene phosphatase and tensin homologue partially inhibits wnt-1-induced mammary tumorigenesis.

Zhao H, Cui Y, Dupont J, Sun H, Hennighausen L, Yakar S.

Cancer Res. 2005 Aug 1;65(15):6864-73.

12.

A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha.

Bocchinfuso WP, Hively WP, Couse JF, Varmus HE, Korach KS.

Cancer Res. 1999 Apr 15;59(8):1869-76.

13.
14.

Chromatin effector Pygo2 regulates mammary tumor initiation and heterogeneity in MMTV-Wnt1 mice.

Watanabe K, Fallahi M, Dai X.

Oncogene. 2014 Jan 30;33(5):632-42. doi: 10.1038/onc.2012.620. Epub 2013 Jan 21.

15.

P190B RhoGAP has pro-tumorigenic functions during MMTV-Neu mammary tumorigenesis and metastasis.

McHenry PR, Sears JC, Herrick MP, Chang P, Heckman-Stoddard BM, Rybarczyk M, Chodosh LA, Gunther EJ, Hilsenbeck SG, Rosen JM, Vargo-Gogola T.

Breast Cancer Res. 2010;12(5):R73. doi: 10.1186/bcr2643. Epub 2010 Sep 22.

16.

Wnt signaling, stem cells, and the cellular origin of breast cancer.

Lindvall C, Bu W, Williams BO, Li Y.

Stem Cell Rev. 2007 Jun;3(2):157-68. Review.

PMID:
17873348
17.

Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia.

Li X, Gonzalez ME, Toy K, Filzen T, Merajver SD, Kleer CG.

Am J Pathol. 2009 Sep;175(3):1246-54. doi: 10.2353/ajpath.2009.090042. Epub 2009 Aug 6.

18.

Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors.

Romieu-Mourez R, Kim DW, Shin SM, Demicco EG, Landesman-Bollag E, Seldin DC, Cardiff RD, Sonenshein GE.

Mol Cell Biol. 2003 Aug;23(16):5738-54.

19.

RARα1 control of mammary gland ductal morphogenesis and wnt1-tumorigenesis.

Cohn E, Ossowski L, Bertran S, Marzan C, Farias EF.

Breast Cancer Res. 2010;12(5):R79. doi: 10.1186/bcr2724. Epub 2010 Oct 5.

20.

Conditional deletion of β-catenin in mammary epithelial cells of Ron receptor, Mst1r, overexpressing mice alters mammary tumorigenesis.

Wagh PK, Zinser GM, Gray JK, Shrestha A, Waltz SE.

Endocrinology. 2012 Jun;153(6):2735-46. doi: 10.1210/en.2011-1543. Epub 2012 Apr 2.

Items per page

Supplemental Content

Write to the Help Desk